CAMIL regression predicts continuous homologous-recombination deficiency and tumor immune biomarkers from histology
A self-supervised, attention-based deep-learning regression model predicted continuous homologous-recombination deficiency (HRD) scores and tumor-microenvironment biomarkers from H&E pathology slides. On TCGA internal validation, HRD classification AUROC exceeded 0.70 in five of seven cancer types; external CPTAC validation reached AUROC 0.81 for lung adenocarcinoma and 0.96 for endometrial cancer. In 2,297 colorectal-cancer patients in the DACHS cohort, continuous regression scores for leukocyte fraction and lymphocyte-infiltration-related signatures were independently prognostic in multivariable survival analysis.
Technology: CAMIL regression, a self-supervised contrastive-clustering and attention-based multiple-instance deep-learning model
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: On TCGA internal validation, HRD classification AUROC exceeded 0.70 in five of seven cancer types; external CPTAC validation reached AUROC 0.81 for lung adenocarcinoma and 0.96 for endometrial cancer.
- Still unknown: Retrospective computational pathology analysis; the model predicts molecular and immune-related biomarkers from slides and does not replace confirmatory molecular testing or establish treatment selection benefit. HRD performance varied by cancer type, with weak internal performance in some cohorts. The reported survival associations in DACHS are prognostic associations, not evidence that using model predictions improves patient outcomes. Scores and endpoints were tested in the named datasets.
- AI role: The model analyzed whole-slide H&E images to estimate continuous HRD and tumor-microenvironment biomarker scores. The team compared regression with classification methods across cohorts, externally validated HRD predictions in CPTAC, and tested prognostic associations of predicted scores in a separate retrospective colorectal-cancer cohort.
Evidence sources: https://www.nature.com/articles/s41467-024-45589-1.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 126 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.